Comparison of human mesenchymal stem cells derived from adipose and cord tissue

Choudhery, Mahmood S; Badowski, Michael; Muise, Angela; Harris, David T.

doi:10.1016/j.jcyt.2012.11.010

Cited by 112 publications

(100 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…SSEA-4 is an early embryonic carbohydrate antigen usually used to label human micro differential pluripotent embryonic stem cells and embryo decomposition products at the blastocyst stage. Our cells were negative for SSEA-4, consistent with previous reports [31][32][33][34] . HLA-DR was also negative, which confirmed the immunogenicity of MSCs.…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

Comparative analysis of biological characteristics of adult mesenchymal stem cells with different tissue origins

Chen

Mou

et al. 2015

Asian Pacific Journal of Tropical Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

“…CD44 is an important adhesion molecule that supports and promotes the migration of MSCs [34] . CD44 expression was 10-fold higher in MenSCs compared with UCMSCs and BMSCs, suggesting that MenSCs had stronger adhesion ability in culture.…”

Section: Discussionmentioning

confidence: 99%

Comparative analysis of biological characteristics of adult mesenchymal stem cells with different tissue origins

Chen

Mou

et al. 2015

Asian Pacific Journal of Tropical Medicine

View full text Add to dashboard Cite

show abstract

“…Although bone marrow is the main source, MSCs have already been isolated from various other tissues, such as adipose tissue (22) and umbilical cord (23). Choudhery et al (24) reported that confluent cultures of MSCs either from adipose tissue or cord tissue show a fibroblastic morphology. They further demonstrated that the isolated MSCs are positive for CD44, CD73, CD90, and CD105 and negative for the hematopoietic markers CD3, CD14, CD19, CD34, and CD45.…”

Section: Discussionmentioning

confidence: 99%

Delivery of the Sox9 gene promotes chondrogenic differentiation of human umbilical cord blood-derived mesenchymal stem cells in an in vitro model

Wang

et al. 2014

Braz J Med Biol Res

View full text Add to dashboard Cite

SRY-related high-mobility-group box 9 (Sox9) gene is a cartilage-specific transcription factor that plays essential roles in chondrocyte differentiation and cartilage formation. The aim of this study was to investigate the feasibility of genetic delivery of Sox9 to enhance chondrogenic differentiation of human umbilical cord blood-derived mesenchymal stem cells (hUC-MSCs). After they were isolated from human umbilical cord blood within 24 h after delivery of neonates, hUC-MSCs were untreated or transfected with a human Sox9-expressing plasmid or an empty vector. The cells were assessed for morphology and chondrogenic differentiation. The isolated cells with a fibroblast-like morphology in monolayer culture were positive for the MSC markers CD44, CD105, CD73, and CD90, but negative for the differentiation markers CD34, CD45, CD19, CD14, or major histocompatibility complex class II. Sox9 overexpression induced accumulation of sulfated proteoglycans, without altering the cellular morphology. Immunocytochemistry demonstrated that genetic delivery of Sox9 markedly enhanced the expression of aggrecan and type II collagen in hUC-MSCs compared with empty vector-transfected counterparts. Reverse transcription-polymerase chain reaction analysis further confirmed the elevation of aggrecan and type II collagen at the mRNA level in Sox9-transfected cells. Taken together, short-term Sox9 overexpression facilitates chondrogenesis of hUC-MSCs and may thus have potential implications in cartilage tissue engineering.

show abstract

“…Adipose derived stem cells (ASCs) are characterized by a phenotypic profile and differentiating capability similar to bone marrow or embryonal derived MSCs (Kern et al, 2006;Baglioni et al, 2009). Several studies have demonstrated that ASCs are able to efficiently differentiate toward adipogenic-chondrogenic-neurogenic-osteogenic-like cells (Quirici et al, 2010;Choudhery et al, 2013), and to modulate biomolecular signals (Gonzalez-Rey et al, 2010;Sacerdote et al, 2013;Nasef et al, 2008;Yoo et al, 2009). In particular, vascular endothelial growth factor (VEGF), epidermal growth factor (EGF) and the transforming growth factor-beta 1 (TGF-b1) belong to the stem cell secretome (Ribeiro et al, 2012;Salgado et al, 2010) and these growth factors have been related to pain modulation and neuroprotection (Kiguchi et al, 2014;Maiese, 2015;Wang et al, 2015).…”

mentioning

confidence: 99%

Adipose-derived stem cells decrease pain in a rat model of oxaliplatin-induced neuropathy: Role of VEGF-A modulation

et al. 2018

View full text Add to dashboard Cite

Keywords:Adipose stem cells Chemotherapy-induced neuropathic pain VEGF-A VEGF 165 b Bevacizumab VEGF-R1 Intrathecal TGF-b1 EGF a b s t r a c t Oxaliplatin therapy of colorectal cancer induces a dose-dependent neuropathic syndrome in 50% of patients. Pharmacological treatments may offer limited relief; scientific efforts are needed for new therapeutic approaches. Therefore we evaluated in a preclinical setting the pain relieving properties of mesenchymal stem cells and its secretome. Rat adipose stem cells (rASCs) were administered in a rat model of oxaliplatin-induced neuropathy.A single intravenous injection of rASCs reduced oxaliplatin-dependent mechanical hypersensitivity to noxious and non-noxious stimuli taking effect 1 h after administration, peaking 6 h thereafter and lasting 5 days. Cell-conditioned medium was ineffective. Repeated rASCs injections every 5 days relieved pain each time with a comparable effect. Labeled rASCs were detected in the bloodstream 1 and 3 h after administration and found in the liver 24 h thereafter. In oxaliplatin-treated rats, the plasma concentration of vascular endothelial growth factor (pan VEGF-A) was increased while the isoform VEGF 165 b was upregulated in the spinal cord. Both alterations were reverted by rASCs. The anti-VEGF-A monoclonal antibody bevacizumab (intraperitoneally) reduced oxaliplatin-dependent pain. Studying the peripheral and central role of VEGF 165 b in pain, we determined that the intraplantar and intrathecal injection of the growth factor induced a pro-algesic effect. In the oxaliplatin neuropathy model, the intrathecal infusion of bevacizumab, anti-rat VEGF 165 b antibody and rASCs reduced pain.Adult adipose mesenchymal stem cells could represent a novel approach in the treatment of neuropathic pain. The regulation of VEGF-A is suggested as an effective mechanism in the complex response orchestrated by stem cells against neuropathy.

show abstract

Comparison of human mesenchymal stem cells derived from adipose and cord tissue

Cited by 112 publications

References 46 publications

Comparative analysis of biological characteristics of adult mesenchymal stem cells with different tissue origins

Comparative analysis of biological characteristics of adult mesenchymal stem cells with different tissue origins

Delivery of the Sox9 gene promotes chondrogenic differentiation of human umbilical cord blood-derived mesenchymal stem cells in an in vitro model

Adipose-derived stem cells decrease pain in a rat model of oxaliplatin-induced neuropathy: Role of VEGF-A modulation

Contact Info

Product

Resources

About